Longevity & Cellular HealthAvailable
MOTS-c
A mitochondrial-derived peptide studied in metabolic regulation and exercise physiology.
LongevityEnergyWeight Management
Clinical review required · Pricing after approval
SS-31
A mitochondria-targeted peptide studied in cardiolipin stabilisation and cellular energetics.
AvailableClinical review requiredPricing released after approval
LongevityEnergyRecovery
What it is
SS-31 (elamipretide) is a tetrapeptide that concentrates in the inner mitochondrial membrane.
How it works
It binds cardiolipin, stabilising cristae architecture and improving electron-transport efficiency.
Why it may be considered
One of the more mechanistically interesting agents in longevity medicine, with human trials still ongoing.
Who may be a candidate
- You are an established MECCA patient, or are willing to begin with a consultation.
- You have a clearly defined goal that this therapy plausibly addresses.
- Your recent laboratory work and history have been reviewed by your clinician.
- You are able to attend the monitoring intervals the protocol requires.
Who may not be a candidate
- You are pregnant, breastfeeding, or planning pregnancy.
- You have an active malignancy or an unresolved undiagnosed symptom.
- You take a medication that interacts with this therapy.
- Your goal is better served by training, nutrition, sleep or an existing prescription.
Typical treatment-review considerations
- Current medications, supplements and prescriptions written elsewhere.
- Relevant baseline testing, and whether an interval draw is needed first.
- Monitoring cadence, expected review date and the criteria for stopping.
- Whether a non-pharmacologic route addresses the same goal first.
Safety considerations
- Prescription-only. Never self-source or self-administer outside a supervised plan.
- Injection-site reactions, bruising and transient discomfort are the most commonly reported effects.
- Report any new or unexpected symptom to your care team before the next scheduled dose.
Frequently asked
About SS-31.
You can submit a request, but it cannot be approved until a licensed clinician has reviewed your history. If you are not yet a patient, your request opens a consultation rather than a prescription.
No. Pricing is released with your approved plan, after a clinician has decided the therapy is appropriate for you.
Often, yes. A request tells us what you are interested in. The recommendation you receive reflects your goals, history, medications and testing.
Related products
Considered alongside this therapy.
Longevity & Cellular HealthAvailable
NAD+
A cellular cofactor central to energy metabolism, delivered by infusion or injection.
LongevityEnergyCognitive Health
Clinical review required · Pricing after approval
Related education
What to understand before you request this.
How we think about safety.
Prescription therapy carries risk. We name the monitoring a therapy requires, the symptoms that should stop it, and the criteria for reviewing it again.
Read the medical disclaimer →How MECCA approaches therapy.
Measure, interpret, intervene, re-measure. Nothing is prescribed without a baseline, a defined goal and a scheduled point at which the plan is revisited.
Learn our approach →What happens after you request.
A request opens a clinical conversation. A licensed clinician decides what is appropriate, and pricing is released only with an approved plan.
See how ordering works →Clinical-review disclaimer — This page is educational and is not medical advice, a recommendation, or an offer to sell. No therapy described here can be dispensed without a prescription from a licensed clinician who has reviewed your history. MECCA does not publish dosing instructions or patient pricing, and requesting a product does not guarantee approval.
Begin with a conversation
A thirty-minute consultation, with a physician, at no cost.
We'll talk through your history and goals and tell you honestly whether MECCA is the right fit. No pressure, no packages, no obligation.